A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer
BMC Cancer - United Kingdom
doi 10.1186/s12885-017-3174-z
Full Text
Open PDFAbstract
Available in full text
Date
March 14, 2017
Authors
Publisher
Springer Science and Business Media LLC